Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zahid Ali

Emergency Medicine Easley, SC Medical Doctor

NPI 1437110673 CMS profile 200545

129 Fleetwood Dr, Easley, SC 29640

Open in the dashboard

General payments

$5,224

368 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zahid Ali of Easley, SC is reported in the CMS Open Payments database as having received $5,224 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $370 21
2024 General $201 11
2023 General $569 37
2022 General $935 69
2021 General $1,302 94
2020 General $1,094 74
2019 General $754 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zahid Ali
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Zahid Ali were reported at $370. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Zahid Ali Emergency Medicine median Middle half National median
2019 $754 $51 $18–$128 $163
2020 $1,094 $29 $16–$99 $114
2021 $1,302 $40 $18–$124 $132
2022 $935 $49 $20–$134 $149
2023 $569 $51 $22–$142 $160
2024 $201 $52 $22–$150 $164
2025 $370 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,756 139 payments
  2. Janssen Pharmaceuticals, Inc $998 79 payments
  3. Novartis Pharmaceuticals Corporation $441 29 payments
  4. Amgen Inc. $382 25 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $320 17 payments
  6. AstraZeneca Pharmaceuticals LP $268 17 payments
  7. Merck Sharp & Dohme Corporation $254 16 payments
  8. Pfizer Inc. $194 13 payments
  9. Esperion Therapeutics, Inc. $118 7 payments
  10. Amarin Pharma Inc. $113 6 payments
  11. Other $380 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,198 366 payments
  2. Education $26 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $998 79 payments
  2. MERLIN@HOME $446 34 payments
  3. Repatha $382 25 payments
  4. JARDIANCE $301 16 payments
  5. ENTRESTO $261 18 payments
  6. VERQUVO $254 16 payments
  7. Merlin Connectivity and Remote Cardiac Rhythm Management $205 18 payments
  8. ELIQUIS $194 13 payments
  9. LEQVIO $180 11 payments
  10. Merlin Connectivity and Remote Cardiac Arrhythmias and Heart Failure $161 13 payments
  11. Other $2,139 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

3,229

Median for Cardiology: 2,533

Drug cost

$376,604

Median for Cardiology: $485,213

Branded share of claims

27.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 150 $168,406
Xarelto Rivaroxaban Brand 78 $88,772
Entresto Sacubitril/Valsartan Brand 47 $58,693
Repatha Sureclick Evolocumab Brand 34 $26,884
Isosorbide Dinitrate Generic 61 $3,178
Atorvastatin Calcium Generic 336 $2,990
Metoprolol Succinate Generic 244 $2,911
Ranolazine Er Ranolazine Brand 38 $2,824
Potassium Chloride Generic 176 $2,431
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 315 $2,397

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$168,141

Of which drugs: $1,181

Medicare patients

331

Average age 78

Services billed

2,308

165 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Heart failure 73%
Chronic kidney disease 56%
Arthritis 51%
Atrial fibrillation 47%
Diabetes 45%
Depression 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 51 204 $1,009
Injection, aminophyllin, up to 250 mg J0280 Office 28 28 $172

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $56
$56 — —
Repatha
  • Amgen Inc. $31
$31 34 —
XARELTO
  • Janssen Pharmaceuticals, Inc $29
$29 78 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $20
$20 47 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record